PRELIMINARY PROGRAMME

Size: px
Start display at page:

Download "PRELIMINARY PROGRAMME"

Transcription

1 PRELIMINARY PROGRAMME 26 May 2017 ITALIAN LANGUAGE SYMPOSIUM PHARMACOLOGY IN INTERVENTIONAL CARDIOLOGY DAPT AFTER PCI CONTROVERSY 1 - P2Y12 INHIBITION AFTER PCI IN STABLE PATIENTS Clopidogrel remains the best option in real life Direct-acting P2Y12 inhibitors should be preferred CONTROVERSY WHICH P2Y12 INHIBITOR SHOULD WE USE IN ACS? What guidelines suggest What real world registries show LONG-TERM MANAGEMENT OF PCI PATIENTS CONTROVERSY 1 THERAPY IN HIGH RISK PATIENTS Medical therapy optimization with multiple drugs The newer Polypill is the solution CONTROVERSY 2 ADHERENCE TO DRUGS Compliance to treatment as a major determinant of outcome Strategies to improve patient adherence to treatment LUNCH

2 ANTICOAGULATION IN PCI PATIENTS WITH ATRIAL FIBRILLATION CONTROVERSY 1 THE CHOICE OF NOACS AFTER PCI Phase 3 trials only must guide drug selection Real world data help physicians choice CONTROVERSY 2 NOACS IN PCI AND SURGERY Should NOACs be interrupted in case of PCI? How NOACs should be used in case of surgery? THE FUTURE OF ANTIPLATELETS AND ANTICOAGULANTS AFTER PCI CONTROVERSY 1 THE FUTURE OF P2Y12 INHIBITION Life long dual antiplatelet therapy Only ticagrelor without aspirin CONTROVERSY 2 THE FUTURE OF NOACS Will NOACs and aspirin never be associated? Will NOACs become indicated also in patients with SCA? PARALLEL WORKSHOP ABOUT CLINICAL TRIALS 26 MAY Welcome introduction and course objectives Giuseppe Rosano (UK), Sven Wassmann (Germany) Perspectives of an Editor-In-Chief Stefan Agewall (Norway) SESSION 1. HOW TO DESIGN AND RUN A CLINICAL TRIAL An overview of the different aspects of clinical trials A. Niessner

3 09.50 Traditional versus novel trial designing Giuseppe Rosano (UK) Planning and organising a clinical trial Basil Lewis (Israel) The logistics of running a clinical trial Basil Lewis (Israel) Refreshments and networking SESSION 2. REGULATORY ASPECTS Requirements from regulatory agencies: endpoints, comparators, type of studies Giuseppe Rosano (UK) Post marketing surveillance T. Walther Lunch and networking SESSION 3. TRIAL CATEGORIES Observational trials and registries G. L. Savarese (Italy) Randomised controlled trials A. Niessner Meta-analyses and systematic reviews G. L. Savarese (Italy) SESSION 4. WHAT S NEXT UPCOMING AND ONGOING CLINICAL TRIALS ACS / Antithrombotics Basil Lewis (Israel) / S. Wassmann (Germany) Lipidology H. Drexel (Austria) Diabetes H. Drexel (Austria) Heart Failure M. Lainscack (Slovenia) Refreshments and networking

4 SESSION 5: GOOD CLINICAL PRACTICE GCP for the busy investigator (certificate included) D. Rolfe Close of day 1 27 MAY Welcome and objectives Giuseppe Rosano (UK), Sven Wassmann (Germany) STATISTICAL ISSUES IN CLINICAL TRIALS BASIC NOTIONS Parallel groups (switch after 60 min): Randomised controlled trials and subgroup analyses - A. Niessner Registries and meta-analyses - G.L. Savarese Refreshments and networking HOW TO INTERPRET CLINICAL TRIAL DATA Examples from recent clinical trials S. Wassmann (Germany) + Panelists THINGS TO KNOW FOR JUNIOR INVESTIGATORS Parallel groups: How to write a manuscript - S. Wassmann (Germany) What you need to know as junior investigator - G. Rosano (UK) Closing remarks G. Rosano (UK), S. Wassmann (Germany) Lunch and networking Close of day 2

5 26 May EuroCVP 2017 OPENING CEREMONY END OF DAY 1 27 May 2017 NEW TARGETS IN THE PREVENTION OF CARDIOVASCULAR DISEASE Chairs: Basil Lewis (Israel), Stefan Agewall (Norway) The pharmacological and non-pharmacological approach to cardiovascular prevention Massimo Piepoli (Italy) The management of lipid profile according to the ESC Guidelines Heinz Drexel (Austria) Management of altered glucose metabolism Itamar Raz (Israel) DIABETES MELLITUS: A CARDIOVASCULAR DISEASE Chairs: Stefan Anker (Germany), Massimo Piepoli (Italy) Cardiovascular risk in diabetics Gianluigi Savarese (Sweden) Lenient or intensive control of glycaemia? Itamar Raz (Israel) Effective at last The new glucose-lowering drugs that reduce cardiovascular events Thomas Walther (Ireland)

6 12.30 LUNCHEON SYMPOSIUM PHARMACOLOGY OF ANTI-ISCHAEMIC THERAPY HOW TO TREAT THE DIFFICULT PATIENT? Chairs: Claudio Ceconi (Italy), Juan Carlos Kaski (UK) Elderly patients with heart failure co-morbidities Andrew Coats (UK) Patients with acute coronary syndromes receiving oral anticoagulants Torp Pederson (Denmark) Ischaemic heart failure with renal and/or liver failure Claudio Ceconi (Italy) Joint Session with the HEART FAILURE ASSOCIATION PHARMACOTHERAPY OF HEART FAILURE Chairs: Petar Seferovic (Serbia), Thomas Walther (Ireland) How to implement the pharmacological therapy of patients with HFrEF Stefan Anker (Germny) Optimisation of RAASi How can we manage K+ Lars Lund (Sweden) The treatment of patients with advanced heart failure Marco Metra (Italy) END OF DAY 2

7 28 May 2017 UPDATE ON ORAL ANTICOAGULATION Chairs: Juan Tamargo (Spain), Thomas Schmidt (Denmark) NOACs for patients with venous thromboembolism and atrial fibrillation Alexander Niessner (Austria) How can we individualise NOACs in everyday practice? Giuseppe Rosano (UK) Anticoagulation in the difficult patient: how to choose the right drug Sven Wassmann (Germany) 10:30 OPEN COFFEE BREAK WITH PANEL DISCUSSION NOAC antidotes. How relevant for clinical practice? Panel: Basil Lewis (Israel), Alexander Niessner (Austria), Giuseppe Rosano (UK), Sven Wassmann (Germany) Current status of antidotes and reversal agents for NOAC Juan Tamargo (Spain) MODERN MANAGEMENT OF CHRONIC ISCHAEMIC HEART DISEASE Chairs: Maurizio Volterrani (Italy) Dan Atar (Norway) Targets for the modern pharmacologic treatment of chronic ischaemic heart disease Juan Carlos Kaski (UK) Combination therapy for the optimal management of chronic stable angina Giuseppe Rosano (UK) Heart rate and cardiac metabolism optimisation Maurizio Volterrani (Italy) Closing discussion END OF DAY 3

8 Organisers EUROPEAN SOCIETY OF CARDIOLOGY The European Heart House Les Templiers 2035 route des colles CS BIOT Sophia Antipolis Cedex France MICOM Srl Via B. Verro, Milan Italy Supported by: Società Italiana di Cardiologia (SIC) Societa' Italiana Cardiologia Ospedalita' Accreditata (SICOA) (Requests pending) Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Italian Heart Failure Association (ITAHFA) CME Provider and Secretariat MICOM Srl Via B. Verro, Milan Italy Tel Fax info@eurocvp.com Website: Location: NH Collection Roma Vittorio Veneto Corso D'Italia Rome Italy

ANNUAL REPORT

ANNUAL REPORT Identification Working Group on: Cardiovascular Pharmacotherapy Nucleus Composition (Sept 2014-Sept 2016) (Precise name, surname and country) Chairperson:... Vice-chairperson & Secretary... Past Chairperson...

More information

EuroCVP Rome, Italy May, 2017 SCIENTIFIC PROGRAMME

EuroCVP Rome, Italy May, 2017 SCIENTIFIC PROGRAMME EuroCVP 2017 26-28 May, 2017 SCIENTIFIC PROGRAMME EuroCVP 2017 26-28 May, 2017 WELCOME MESSAGE SCIENTIFIC RATIONALE There is compelling evidence that in patients with cardiovascular disease and in those

More information

08:45-09:00 S1: Opening Ceremony Hall A Chairs: Stefan Agewall, Norway; Basil S. Lewis, Israel

08:45-09:00 S1: Opening Ceremony Hall A Chairs: Stefan Agewall, Norway; Basil S. Lewis, Israel Final Programme as at 16 May, 2016 Session times are subject to changes Sunday, 29 May 2016 08:00-17:00 Registration 08:45-09:00 S1: Opening Ceremony Hall A Chairs: Stefan Agewall, Norway; Basil S. Lewis,

More information

DAPT Essential Messages from ESC Guidelines. Committee for Practice Guidelines

DAPT Essential Messages from ESC Guidelines. Committee for Practice Guidelines 2017 Essential Messages from ESC Guidelines Committee for Practice Guidelines DAPT Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Essential Messages 2017 ESC focused update on dual

More information

CARDIOLOGY I BREAKOUT SESSIONS. May Lisbon PORTUGAL Hotel da Estrela. Atrial Fibrillation/ Venous TromboEmbolism

CARDIOLOGY I BREAKOUT SESSIONS. May Lisbon PORTUGAL Hotel da Estrela. Atrial Fibrillation/ Venous TromboEmbolism BREAKOUT SESSIONS CARDIOLOGY I Atrial Fibrillation/ Venous TromboEmbolism Advanced Clinical Knowledge for Pharmacists www.hcpa.pt OUR EXPERTS Helen Williams MRPharmS PGDip(Cardiol) Ipresc \ Consultant

More information

CURRENT STRATEGIES TO OPTIMALLY TREAT PATIENTS WITH DIABETES AND CVD

CURRENT STRATEGIES TO OPTIMALLY TREAT PATIENTS WITH DIABETES AND CVD Associazione Chaira Medica This event is compliant with the Eucomed Code of Ethical Business Practice (www.ethicalmedtech.eu) 5 th Post-graduate Updating Course CURRENT STRATEGIES TO OPTIMALLY TREAT PATIENTS

More information

A Patient with Chest Pain and Atrial Fibrillation

A Patient with Chest Pain and Atrial Fibrillation A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi

More information

American College of Cardiology 66th Annual Scientific Session (ACC.17):

American College of Cardiology 66th Annual Scientific Session (ACC.17): News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American College of Cardiology 66th Annual Scientific

More information

Essential Messages from ESC Guidelines

Essential Messages from ESC Guidelines Essential Messages from ESC Guidelines Committee for Practice Guidelines AMI-STEMI 2017 Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation Essential

More information

News Release. For UK Media

News Release. For UK Media News Release For UK Media Bayer plc 400 South Oak Way Reading RG2 6AD www.bayer.co.uk Bayer s Xarelto (rivaroxaban) in combination with single antiplatelet therapy receives positive CHMP opinion for treatment

More information

New Study Presented at American Heart Association (AHA) Scientific Sessions 2016:

New Study Presented at American Heart Association (AHA) Scientific Sessions 2016: Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions

More information

Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원

Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants

More information

Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim

Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel

More information

After acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy

After acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel

More information

Additional Contributor: Glenn Levine (USA).

Additional Contributor: Glenn Levine (USA). 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management

More information

Bayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study

Bayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:

More information

SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?

SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? tielle est 2 ré Totielle est interdite. Prof. Marco Roffi Hôpitaux Universitaires de Genève Research funding

More information

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current

More information

8 th Congress of ECCO

8 th Congress of ECCO European Crohn s and Colitis Organisation Vienna Austria 8 th Congress of ECCO Austria Center Vienna February 14-16, 2013 The major educational event in the field of Inflammatory Bowel Diseases in Europe

More information

Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT

Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Potential conflicts of interest In the past 2 years Felicita

More information

Mastering the treatment of Depression and Schizophrenia

Mastering the treatment of Depression and Schizophrenia Florence January 17-18, 2017 Palazzo dei Congressi Piazza Adua, 1 Course Director: Andrea Fagiolini Mastering the treatment of Depression and Schizophrenia Advanced Psychopharmacology Course RATIONALE

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Chairpersons Christian W. Hamm Medical Clinic

More information

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators

More information

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation

2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation Thierry Gillebert European Society of Cardiology, Slides kindly provided

More information

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes 8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific

More information

High-sensitive troponin. Introduction. Platelet aggregation inhibition at admission

High-sensitive troponin. Introduction. Platelet aggregation inhibition at admission Neth Heart J (2017) 25:181 185 DOI 10.1007/s12471-016-0939-y GUIDELINES 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:

More information

Optimal lenght of DAPT in different clinical scenarios

Optimal lenght of DAPT in different clinical scenarios Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk

More information

National Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation

National Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of

More information

Cardio-Pulmonary Update 2013 August 9-21, Detailed Conference Agenda

Cardio-Pulmonary Update 2013 August 9-21, Detailed Conference Agenda Cardio-Pulmonary Update 2013 August 9-21, 2013 Detailed Conference Agenda Please Note: Out of respect for your fellow delegates, please arrive at least 5 minutes prior to each session. The sessions will

More information

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban

More information

24 th Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy (ISCP)

24 th Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy (ISCP) 24 th Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy (ISCP) Lugano Switzerland Thursday, May 9 th and Friday, May 10 th 2019 Organized in collaboration with the Working

More information

Stable CAD, Elective Stenting and AFib

Stable CAD, Elective Stenting and AFib Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1

More information

Zürcher Herzkurs, New drugs and interactions. LDL - what else?

Zürcher Herzkurs, New drugs and interactions. LDL - what else? Zürcher Herzkurs, 29.09.2017 New drugs and interactions LDL - what else? Heinz Drexel, MD, FESC, FAHA, FRCP (Ed.) VIVIT Institut am Akademischen Lehrkrankenhaus Feldkirch, A Private Universität im Fürstentum

More information

When and how to combine antiplatelet agents and anticoagulant?

When and how to combine antiplatelet agents and anticoagulant? When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation

More information

PRELIMINARY PROGRAMME. 2nd European-Middle East Forum on Managing cardiovascular risk factors in clinical practice 6 December, Istanbul, Turkey

PRELIMINARY PROGRAMME. 2nd European-Middle East Forum on Managing cardiovascular risk factors in clinical practice 6 December, Istanbul, Turkey PRELIMINARY PROGRAMME 2nd European-Middle East Forum on Managing cardiovascular risk factors in clinical practice 6 December, 2013 - Istanbul, Turkey Background and aims of the conference Cardiovascular

More information

FLORENCE SPORT MEDICINE FLORENCE LIFESTYLE: FROM ATHLETES TO THE PATIENTS

FLORENCE SPORT MEDICINE FLORENCE LIFESTYLE: FROM ATHLETES TO THE PATIENTS FLORENCE SPORT MEDICINE LIFESTYLE: FROM ATHLETES TO THE PATIENTS preliminary program Promoted by Organized by Mirone di Eleutère, Discobolo Lancellotti, Museo nazionale romano di Palazzo Massimo - Roma

More information

Advance Programme ACUTE CARDIOVASCULAR CARE2015 EUROPEAN SOCIETY OF CARDIOLOGY

Advance Programme ACUTE CARDIOVASCULAR CARE2015 EUROPEAN SOCIETY OF CARDIOLOGY Advance Programme ACUTE CARDIOVASCULAR CARE2015 EUROPEAN SOCIETY OF CARDIOLOGY 08:30 10:00 Saturday 17 October 2015 Zeremoniensaal Prinz Eugen Saal Rittersaal Gartensaal Neurologic emergencies Acute cardiovascular

More information

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media

Bayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the

More information

Update on public hearing

Update on public hearing Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity

More information

Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely

Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1

More information

Preliminary Programme

Preliminary Programme Preliminary Programme The scientific programme comprises various styles of presentations and sessions, each offering a unique opportunity to amass new and important scientific information. Optimal management

More information

pat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16

pat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE

More information

FLORENCE SPORT MEDICINE FLORENCE LIFESTYLE: FROM ATHLETES TO THE PATIENTS

FLORENCE SPORT MEDICINE FLORENCE LIFESTYLE: FROM ATHLETES TO THE PATIENTS FLORENCE SPORT MEDICINE LIFESTYLE: FROM ATHLETES TO THE PATIENTS preliminary program Promoted by Organized by Mirone di Eleutère, Discobolo Lancellotti, Museo nazionale romano di Palazzo Massimo - Roma

More information

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate

More information

BRIEF OPENING OF THE MEETING Paolo Ferrari, Chief Medical Officer, Ente Ospedaliero Cantonale WORLD EPIDEMICS JOIN

BRIEF OPENING OF THE MEETING Paolo Ferrari, Chief Medical Officer, Ente Ospedaliero Cantonale WORLD EPIDEMICS JOIN Preliminary Programme Lugano Scientific Meeting of the 24th International Society of Cardiovascular Pharmacotherapy (ISCP) Palazzo dei Congressi, Lugano, Switzerland May 9th 10th 2019 Credits Swiss Society

More information

Scope of the Problem: DAPT and Triple Therapy after Stenting

Scope of the Problem: DAPT and Triple Therapy after Stenting Scope of the Problem: DAPT and Triple Therapy after Stenting Kurt Huber, MD, FESC, FACC 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Session, August 30, 2010,

More information

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation

More information

EULAR-PReS PAEDIATRIC MUSCULOSKELETAL COURSE. Monday 12th Wednesday 14th June 2017 Madrid, Spain

EULAR-PReS PAEDIATRIC MUSCULOSKELETAL COURSE. Monday 12th Wednesday 14th June 2017 Madrid, Spain EULAR-PReS PAEDIATRIC MUSCULOSKELETAL COURSE Monday 12th Wednesday 14th June 2017 Madrid, Spain ORGANISATION AND COMMITTEE Scientific organisers Esperanza Naredo Tadej Avcin Jelena Voijinovic Paz Collado

More information

Engagement in language assessment / Regions of Europe

Engagement in language assessment / Regions of Europe Summary table: Engagement in language / Regions of This table lists the statistically significant differences in the engagement in activities by the respondents from different s of : If the word or appears

More information

Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015

Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Wesam A Alhejily MD FRCPC FACP FACC FSCAI Assistant Professor of Medicine Chief Of Adult Cardiology Consultant

More information

For more information

For more information For more information www.escardio.org/guidelines ESC Guidelines on the Prevention, Diagnosis and Treatment of Infective Endocarditis (New Version 2009)* The Task Force on the Prevention, Diagnosis and

More information

Peer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?

Peer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine? 20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the

More information

Apixaban for stroke prevention in atrial fibrillation. August 2010

Apixaban for stroke prevention in atrial fibrillation. August 2010 Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK. Advances in Cardiac Arrhythmias and Great Innovations in Cardiology

NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK. Advances in Cardiac Arrhythmias and Great Innovations in Cardiology NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK Advances in Cardiac Arrhythmias and Great Innovations in Cardiology Torino, October 15, 2016 Giuseppe Di Pasquale Direttore Dipartimento Medico

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

V Baltic Heart Failure Meeting and Arrhythmias Baltica October Bellevue Park Hotel Riga, 1 Slokas Street, Riga, Latvia Scientific Programme

V Baltic Heart Failure Meeting and Arrhythmias Baltica October Bellevue Park Hotel Riga, 1 Slokas Street, Riga, Latvia Scientific Programme October 20 V Baltic Heart Failure Meeting and Arrhythmias Baltica 20 21 October Bellevue Park Hotel Riga, 1 Slokas Street, Riga, Latvia Scientific Programme 09:00 12:00 Registration 12:00 12:20 OPENING

More information

Overview of European Consumption Databases

Overview of European Consumption Databases FEDERAL INSTITUTE FOR RISK ASSESSMENT Overview of European Consumption Databases Katrin Büsch Workshop Food Consumption Data and Dietary Exposure in the European Union, 15-16 May 2008, Berlin Introduction

More information

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017 WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017 Mary L. Yost 404-520-6652 , LLC 23 Ridge Rd. Beaufort, SC 20097 Copyright Pending 2017 All rights reserved,

More information

October 25-26, 2018 Infinity Hotel & Conference Resort, Munich, Germany

October 25-26, 2018 Infinity Hotel & Conference Resort, Munich, Germany Programme 4 th CVOT Summit in cooperation with D&CVD EASD Study Group October 25-26, 2018 Infinity Hotel & Conference Resort, Munich, Germany Thursday, October 25, 2018 Room Ammersee I 18:00 18:30 Welcome,

More information

REGISTER TODAY! February 9, Sheraton Mahwah Hotel. Program Directors 2 ND ANNUAL COMPREHENSIVE CV DISEASE MANAGEMENT:

REGISTER TODAY! February 9, Sheraton Mahwah Hotel. Program Directors 2 ND ANNUAL COMPREHENSIVE CV DISEASE MANAGEMENT: 2 ND ANNUAL COMPREHENSIVE CV DISEASE MANAGEMENT: FROM FUNDAMENTALS TO INNOVATION 2018 February 9, 2018 7 am - 5 pm CME Symposium Sheraton Mahwah Hotel 1 International Blvd. (Rte. 17 North) Mahwah, NJ 07495

More information

2015 Preliminary Agenda

2015 Preliminary Agenda 2015 Preliminary Agenda Revised 10/08/15 THURSDAY, NOVEMBER 12, 2015 PRE-COURSE WORKSHOP LEARNING OBJECTIVES: At the conclusion of this activity, participants will be better able to: 1. Identify subtle

More information

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen

PCI in Patients with AF Optimizing Oral Anticoagulation Regimen PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and

More information

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients

More information

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,

More information

EULAR-PReS PAEDIATRIC MUSCULOSKELETAL COURSE. Monday 12th Wednesday 14th June 2017 Madrid, Spain

EULAR-PReS PAEDIATRIC MUSCULOSKELETAL COURSE. Monday 12th Wednesday 14th June 2017 Madrid, Spain EULAR-PReS PAEDIATRIC MUSCULOSKELETAL COURSE Monday 12th Wednesday 14th June 2017 Madrid, Spain ORGANISATION AND COMMITTEE Scientific organisers Esperanza Naredo Tadej Avcin Jelena Vojinovic Paz Collado

More information

Results from the ENSURE-AF study were presented during the ESC Congress 2016 Hot Line session and the full results are published in The Lancet

Results from the ENSURE-AF study were presented during the ESC Congress 2016 Hot Line session and the full results are published in The Lancet Press Release ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo s Once-Daily LIXIANA in Patients with Atrial Fibrillation Undergoing Cardioversion ENSURE-AF is the largest clinical

More information

April 24, Seoul, South Korea

April 24, Seoul, South Korea Clinical Update of Resolute Integrity with DAPT Pooled RESOLUTE Clinical Program Josiah N. Wilcox, Ph.D. Chief Scientific Officer, Coronary and RDN Medtronic CardioVascular TCT-AP TCT AP April 24, 2013

More information

PRELIMINARY PROGRAMME H&N Preceptorship: focus on comprehensive management Nice, France

PRELIMINARY PROGRAMME H&N Preceptorship: focus on comprehensive management Nice, France PRELIMINARY PROGRAMME H&N Preceptorship: focus on comprehensive management Live educational course dates The live educational course H&N Preceptorship: Focus on comprehensive management" will be held on

More information

Cardiac CT Course Part A First step towards level 2 SCCT registration

Cardiac CT Course Part A First step towards level 2 SCCT registration 29 September 2 October 2016 Philips Customer Education Center Business Central Towers, Dubai Internet City, Sheikh Zayed Road, Dubai, UAE The use of Multi-Detector CT (MDCT) in the diagnosis of various

More information

Bayer AG Investor Relations Leverkusen Germany Investor News. Not intended for U.S. and UK Media

Bayer AG Investor Relations Leverkusen Germany   Investor News. Not intended for U.S. and UK Media Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Initiates Xarelto (Rivaroxaban) Study in Patients with Non- Valvular Atrial

More information

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,

More information

Disclosures. Updates in Acute Coronary Syndromes 10/21/17. No Conflicts of Interest. Updates in Acute Coronary Syndromes. Krishan Soni, MD, MBA, FACC

Disclosures. Updates in Acute Coronary Syndromes 10/21/17. No Conflicts of Interest. Updates in Acute Coronary Syndromes. Krishan Soni, MD, MBA, FACC Disclosures Updates in Acute Coronary Syndromes No Conflicts of Interest Krishan Soni, MD, MBA, FACC Assistant Professor of Medicine Division of Cardiology Krishan.soni@ucsf.edu Updates in Acute Coronary

More information

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet

More information

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013

More information

ESSENTIAL MESSAGES FROM ESC GUIDELINES

ESSENTIAL MESSAGES FROM ESC GUIDELINES ESSENTIAL MESSAGES FROM ESC GUIDELINES Committee for Practice Guidelines To improve the quality of clinical practice and patient care in Europe HCM GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC

More information

EDUCATIONAL COURSE. MUSCULOSKELETAL ULTRASOUND in RHEUMATOLOGY BASIC COURSE. Course Coordinator Annamaria Iagnocco

EDUCATIONAL COURSE. MUSCULOSKELETAL ULTRASOUND in RHEUMATOLOGY BASIC COURSE. Course Coordinator Annamaria Iagnocco EDUCATIONAL COURSE 2019 MUSCULOSKELETAL ULTRASOUND in RHEUMATOLOGY BASIC COURSE Rome, March 21-23, 2019 Course Coordinator Annamaria Iagnocco COURSE PRESENTATION Musculoskeletal ultrasound in rheumatology

More information

Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo

Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo Xarelto (Rivaroxaban) Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery

More information

Triple Therapy After PCI in AF: A Quagmire Soon to be Drained

Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT

More information

Case Challenges in ACS The Very Elderly in the Cath Lab

Case Challenges in ACS The Very Elderly in the Cath Lab Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive

More information

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual

More information

ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE

ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE HELEN WILLIAMS FFRPS, MRPHARMS, PGDIP (CARDIOL) IPRESC CONSULTANT PHARMACIST FOR CVD, SOUTH LONDON CLINICAL LEAD FOR ATRIAL FIBRILLATION, HEALTH INNOVATION

More information

Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom?

Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Patients (%) Patients

More information

Subsequent management and therapies

Subsequent management and therapies ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY

More information

Biot Technologies for life. Advanced International Inergetix Seminar: Energy and Informational Medicine on Quantum Base

Biot Technologies for life. Advanced International Inergetix Seminar: Energy and Informational Medicine on Quantum Base Biot Technologies for life is pleased to invite you to the new Advanced International Inergetix Seminar: Energy and Informational Medicine on Quantum Base Practical methods for use of the Inergetix CoRe

More information

6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia

6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia 6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac

More information

Dual Antiplatelet Therapy: Time for a Paradigm Shift?

Dual Antiplatelet Therapy: Time for a Paradigm Shift? Dual Antiplatelet Therapy: Time for a Paradigm Shift? 5 years after PLATO Experience from the Daily Clinical Practice Hans Rickli Goals with antithrombotic treatment Acute coronary syndrome Risk reduction

More information

Summary of Research and Writing Activities In Cardiovascular Disease

Summary of Research and Writing Activities In Cardiovascular Disease Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts

More information

LIQUID BIOPSY: TRACKING CANCER

LIQUID BIOPSY: TRACKING CANCER A.R.Ger.On ONLUS SYMPOSIUM LIQUID BIOPSY: TRACKING CANCER 29-30 April 2016 prog ram Pierre-Auguste Renoir Chemin montant dans les hautes herbes SYMPOSIUM LIQUID BIOPSY: TRACKING CANCER President Paola

More information

US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation

US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation Press Release For non-us Healthcare Media Boehringer Ingelheim GmbH Corporate Communications US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular

More information

New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017

New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017 New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017 A sub-analysis of the ENGAGE AF-TIMI 48 trial found that edoxaban had

More information

BOLZANO March 21-23, 2019

BOLZANO March 21-23, 2019 BOLZANO March 21-23, 2019 Parkhotel Laurin Under the auspices of OrganizATION AND COMMITTE Scientific DIRECTOR Prof. Christian Dejaco Rheumatology Unit Azienda Sanitaria Alto Adige Hospital Brunico-Bruneck

More information

PCHF. A novel course in heart failure management POSTGRADUATE COURSE IN HEART FAILURE

PCHF. A novel course in heart failure management POSTGRADUATE COURSE IN HEART FAILURE PCHF POSTGRADUATE COURSE IN HEART FAILURE A novel course in heart failure management Certified by the European Society of Cardiology (ESC) and the University of Zurich. Based on the new curriculum of the

More information

WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA

WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA September 2017 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe Marmorvej

More information

EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium

EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV GUY DE BACKER Ghent University,Belgium ESC Congress 2012, aug.25-29th, Munich, Germany ESC Congress 2012, aug.25-29th, Munich,

More information

FLORENCE SPORT MEDICINE FLORENCE LIFESTYLE: FROM ATHLETES TO THE PATIENTS

FLORENCE SPORT MEDICINE FLORENCE LIFESTYLE: FROM ATHLETES TO THE PATIENTS FLORENCE SPORT MEDICINE LIFESTYLE: FROM ATHLETES TO THE PATIENTS Promoted by Organized by Mirone di Eleutère, Discobolo Lancellotti, Museo nazionale romano di Palazzo Massimo - Roma FLORENCE CONVITTO DELLA

More information

1 st EULAR-PreS PAED MSUS Course Intermediate

1 st EULAR-PreS PAED MSUS Course Intermediate 1 st EULAR-PreS PAED MSUS Course Intermediate Madrid, Spain Monday, 10 th June Wednesday, 12 th June 2019 The courses are a combination of lectures and hands-on scanning of models (Basic course) or patients

More information

Triple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health

Triple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence

More information